# FDA recall D-1007-2019

> **Rx Pak Division of McKesson Corporation** · Class II · drug recall initiated 2019-01-16.

## Product

Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10

## Reason for recall

Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.

## Distribution

Product was distributed to 5 major distributors who may have further distributed the product throughout the United States.

## Key facts

- **Recall number:** D-1007-2019
- **Recalling firm:** Rx Pak Division of McKesson Corporation
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2019-01-16
- **Report date:** 2019-03-27
- **Termination date:** 2020-12-02

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Memphis, TN, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1007-2019

## Citation

> AI Analytics. FDA recall D-1007-2019. Retrieved 2026-06-01 from https://api.ai-analytics.org/recall/D-1007-2019. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*